A Mitochondrial Inside-Out Iron-Calcium Signal Reveals Drug Targets for Parkinson’s Disease

Vinita Bharat, Aarooran S. Durairaj, Roeland Vanhauwaert, Li Li, Colin M. Muir, Sujyoti Chandra, Chulhwan Kwak, Yann Le Guen, Pawan Nandakishore, Chung-Han Hsieh, Stefano Rensi, Russ B. Altman, Michael D. Greicius, Liang Feng, Xinnan WangbioRxiv 2022 · DOI

TL;DR

This paper uncovers a novel mitochondrial pathway linking iron and calcium dysregulation to Parkinson's Disease (PD). They demonstrate that elevated iron triggers calcium influx into mitochondria, which is sensed by the protein Miro1. This discovery leads to a potential blood test for PD diagnosis and identifies T-type calcium channel blockers as promising therapeutic targets.

What Problem Does This Paper Address?

Parkinson's Disease (PD) is a debilitating neurodegenerative disorder characterized by the loss of dopamine-producing neurons. A major challenge in treating PD is the heterogeneity of the disease, with various genetic and cellular risk factors contributing to its onset and progression. While iron and calcium dysregulation have been individually implicated in PD, the precise mechanistic link between them and their role in disease pathogenesis has remained elusive. This paper aims to elucidate this connection, identify a molecular mechanism, and discover potential therapeutic targets and diagnostic tools.

Methods

The researchers employed a multi-pronged approach:

  • Cellular Models: They used HEK293T cells and patient-derived induced pluripotent stem cells (iPSCs) differentiated into neurons to study the effects of iron and calcium.
  • Biochemical Assays: Techniques like Native-PAGE and Size Exclusion Chromatography (SEC) were used to analyze protein complex assembly and oligomerization. Inductively Coupled Plasma Mass Spectrometry (ICP-MS) was used to quantify iron levels.
  • Live-Cell Imaging: Fluorescent indicators were used to measure real-time changes in cytosolic and mitochondrial calcium levels.
  • Genetic Analysis: Whole-genome sequencing (WGS) data was analyzed to identify rare variants in calcium-related genes associated with PD.
  • Drug Screening: A high-throughput screening (HTP) assay was developed to identify compounds that modulate Miro1 activity.
  • Animal Models: A fly model of PD was used to validate findings in vivo.
  • Biomarker Development: Peripheral blood mononuclear cells (PBMCs) were used to develop a Miro1-based blood test.
  • Machine Learning: Logistic regression models were trained to assess the diagnostic potential of the Miro1 blood test.

Datasets

  • Human Postmortem Brain Tissue: Obtained from individuals with sporadic PD and healthy controls.
  • Human iPSC-derived Neurons: From familial PD patients (SNCA-A53T mutation) and their isogenic wild-type controls, as well as from sporadic PD patients and healthy controls.
  • HEK293T Cells: A standard cell line used for initial mechanistic studies.
  • Peripheral Blood Mononuclear Cells (PBMCs): From healthy donors and PD patients.
  • Whole-Genome Sequencing (WGS) Data: From the Accelerating Medicines Partnership-Parkinson's Disease (AMP-PD) initiative, including cohorts like BioFIND, Harvard Biomarker Study (HBS), and Parkinson's Progression Markers Initiative (PPMI).
  • Genome-Wide Association Study (GWAS) Summary Statistics: Used for identifying common variant associations.

Key Insights and Ideas

  • Iron-Calcium Axis at Mitochondria: The study reveals a critical, previously uncharacterized mitochondrial pathway where elevated iron directly interacts with the Mitochondrial Calcium Uniporter (MCU), leading to increased calcium influx. This is a significant departure from understanding calcium regulation solely at the plasma membrane or ER.
  • Miro1 as a Sensor: Miro1, an outer mitochondrial membrane protein, acts as a crucial sensor for this localized, iron-induced calcium elevation at the outer mitochondrial membrane. This sensing mechanism is key to understanding how mitochondrial calcium dysregulation translates into cellular dysfunction.
  • Miro1 as a Diagnostic Biomarker: The altered Miro1 response to mitochondrial depolarization in PBMCs from PD patients suggests its potential as a reliable blood-based biomarker for PD diagnosis and for monitoring therapeutic response.
  • T-type Calcium Channels as Therapeutic Targets: Genetic analysis points to rare variants in T-type calcium channels being associated with PD. This, combined with drug screening results, highlights T-type calcium channel blockers as promising candidates for PD treatment.

Key Results

  • Iron Promotes MCU Oligomerization: Fe²⁺ treatment of HEK cells led to the formation of higher-order MCU oligomers, enhancing mitochondrial Ca²⁺ uptake.
  • Fe²⁺ Binds Directly to MCU: In vitro binding assays demonstrated that Fe²⁺ directly binds to the MCU complex, with a Kd of 449.3 µM. Mutating key residues in MCU (MCU-3A) abolished this binding and prevented Fe²⁺-induced MCU oligomerization and Ca²⁺ overload.
  • PD Models Mirror Fe²⁺ Effects: Postmortem PD brains and patient-derived neurons showed similar patterns of increased MCU oligomerization and reduced NCLX/MCUb levels as observed in Fe²⁺-treated HEK cells.
  • Miro1 Blood Test Potential: A Miro1 blood test showed significantly higher "Miro1 Ratio" in PD patients compared to controls, suggesting its utility in PD stratification. Machine learning models combining Miro1 Ratio and UPDRS scores achieved an accuracy of 87.8% for PD diagnosis.
  • T-type Calcium Channel Blockers Show Efficacy: Drug screens identified T-type calcium channel blockers (like Benidipine) as potent reducers of Miro1 degradation, suggesting they can mitigate PD-relevant phenotypes in cellular and fly models.

Limitations and Future Work

  • Fly Model Limitations: The fly model lacks an alpha-synuclein homolog, so results may not fully capture the role of human alpha-synuclein in PD.
  • Sample Size: The postmortem brain study had a relatively small sample size, necessitating larger cohorts for confirmation.
  • Pathophysiological Iron Levels: Determining the exact pathophysiological level of free Fe²⁺ in vivo remains challenging.
  • Future Work: The authors suggest further studies with independent cohorts to confirm the Miro1 blood test's promise. Investigating how Fe²⁺ regulates MCUb and NCLX levels, and unraveling the precise roles of Miro in PD pathogenesis and how Ca²⁺ regulates these roles are also highlighted as areas for future research. The potential for personalized drug efficacy testing using patient-derived cells is also proposed.

Summary updated

Abstract

Summary Dysregulated iron or Ca 2+ homeostasis has been reported in Parkinson’s disease (PD) models. Here we discover a connection between these two metals at the mitochondria. Elevation of iron levels causes inward mitochondrial Ca 2+ overflow, through an interaction of Fe 2+ with Mitochondrial Calcium Uniporter. In PD neurons, iron accumulation-triggered Ca 2+ influx across the mitochondrial surface leads to spatially confined Ca 2+ elevation at the outer mitochondrial membrane, which is subsequently sensed by Miro1, a Ca 2+ -binding protein. A Miro1 blood test distinguishes PD patients from controls and responds to drug treatment. Miro1-based drug screens in PD cells discover FDA-approved T-type Ca 2+ -channel blockers. Human genetic analysis reveals enrichment of rare variants in T-type Ca 2+ -channel subtypes associated with PD status. Our results identify a molecular mechanism in PD pathophysiology, and drug targets and candidates coupled with a convenient stratification method.
BibTeX
@misc{bharat2022mitochondrial,
  author = {Vinita Bharat and Aarooran S. Durairaj and Roeland Vanhauwaert and Li Li and Colin M. Muir and Sujyoti Chandra and Chulhwan Kwak and Yann Le Guen and Pawan Nandakishore and Chung-Han Hsieh and Stefano Rensi and Russ B. Altman and Michael D. Greicius and Liang Feng and Xinnan Wang},
  title = {{A Mitochondrial Inside-Out Iron-Calcium Signal Reveals Drug Targets for Parkinson’s Disease}},
  year = {2022},
  doi = {10.1101/2022.10.30.513580},
  howpublished = {bioRxiv},
}
Figure